Diffuse Iris Melanoma: Conservative Treatment with Proton Beam Therapy after Limbal Stem Cell Preservation or Enucleation?
Diffuse iris melanoma
Limbal stem cell deficiency
Proton beam therapy
Journal
Ocular oncology and pathology
ISSN: 2296-4681
Titre abrégé: Ocul Oncol Pathol
Pays: Switzerland
ID NLM: 101656139
Informations de publication
Date de publication:
Oct 2019
Oct 2019
Historique:
received:
20
06
2018
accepted:
11
01
2019
entrez:
27
11
2019
pubmed:
27
11
2019
medline:
27
11
2019
Statut:
ppublish
Résumé
Iris melanomas represent 2-3% of uveal melanomas; the diffuse variant accounts for approximately 10% of all iris melanomas. Different treatment modalities for diffuse iris melanomas (DIM) have been proposed depending on the local status as well as the age and general condition of the patient. This study is a single-centre retrospective case series describing the diagnosis, treatments and outcomes of DIM. Treatment consisted of enucleation or proton beam therapy (PT) of the whole anterior segment. Patients who were treated with PT benefitted from limbal stem cell preservation before irradiation. Between 1996 and 2016, a total of 14 patients with DIM presented to our institution and were included in the database. The global survival was 86%. The median follow-up was 4.6 years (range 4 months to 15 years). Only 1 patient (7%) developed metastatic disease of the DIM (gastric location). No patient developed liver metastasis. Seven patients were treated by enucleation and 7 by PT after limbal stem cell preservation. After a conservative attempt, local tumour recurrence occurred in 2 patients at 2 years, requiring enucleation. The cornea was clear after irradiation in all patients. Cataract ( DIM is a very rare tumour. The global survival is excellent. Conservative treatment with PT is an efficient alternative to enucleation and allows good local tumour control. Cataract and glaucoma are the main radiation-related complications, but the corneal status was excellent due to the stem cell harvest prior to radiotherapy.
Identifiants
pubmed: 31768362
doi: 10.1159/000496847
pii: oop-0005-0396
pmc: PMC6873101
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
396-401Informations de copyright
Copyright © 2019 by S. Karger AG, Basel.
Déclaration de conflit d'intérêts
None of the authors have any conflicts of interests in the matters discussed in the paper.
Références
Eye (Lond). 2007 Jan;21(1):79-82
pubmed: 16410818
Clin Ophthalmol. 2007 Sep;1(3):339-42
pubmed: 19668492
Am J Ophthalmol. 2016 May;165:78-87
pubmed: 26940166
Br J Ophthalmol. 2001 Jun;85(6):666-9
pubmed: 11371484
Ophthalmology. 2002 Aug;109(8):1553-60
pubmed: 12153810
Br J Ophthalmol. 2014 Apr;98(4):484-7
pubmed: 24414401
Ophthalmology. 2001 Jan;108(1):172-8
pubmed: 11150284
Br J Ophthalmol. 2013 Apr;97(4):471-4
pubmed: 23298884
Cornea. 2017 Jan;36(1):119-122
pubmed: 27755196
Am J Ophthalmol. 2003 May;135(5):648-56
pubmed: 12719072
Br J Ophthalmol. 2015 Jun;99(6):812-6
pubmed: 25505288
AMA Arch Ophthalmol. 1958 Feb;59(2):204-14
pubmed: 13497374
Graefes Arch Clin Exp Ophthalmol. 2011 Jun;249(6):937-40
pubmed: 21222214